Attached is a before-and-after photo of a 59-year-old patient treated with *Restylane-L®* and *Restylane® Silk*.

Treatment included: 2.8 mL of *Restylane Silk* in the lips and perioral lines and 1 mL of *Restylane-L* in the nasolabial folds.
Actual, unpaid patient. Individual results may vary. Images have not been retouched.

Please see Important Safety Information for the *Restylane* family of products below and accompanying Instructions for Use.

###

Important Safety Information

Indications: The *Restylane* family of products includes *Restylane®*, *Restylane-L®*, *Restylane® Silk*, *Perlane®*, and *Perlane-L®*. *Restylane*, *Restylane-L*, *Perlane* and *Perlane-L* are indicated for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. *Restylane* and *Restylane-L* are indicated for mid-to-deep dermal implantation; *Perlane* and *Perlane-L* are indicated for implantation into the deep dermis to superficial subcutis. *Restylane Silk* is indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. *Restylane* and *Restylane-L* are also indicated for submucosal implantation for lip augmentation in patients over the age of 21.

Products in the *Restylane* family contain traces of gram-positive bacterial protein and are contraindicated for patients with allergies to such material or in patients with severe allergies that have required in-hospital treatment. These products should not be used by patients with bleeding disorders or by pregnant or breastfeeding women. *Restylane* and *Restylane-L* for lip enhancement and *Restylane Silk* should not be used by people under 22 years. *Restylane-L, Restylane Silk* and *Perlane-L* should not be used by anyone with a known allergy to lidocaine. Products should not be injected anywhere except the dermis, superficial subcutis (*Perlane* and *Perlane-L* only), or lip submucosa (*Restylane, Restylane-L,* and *Restylane Silk* only).

Use of products in the *Restylane* family at the site of skin sores, pimples, rashes, hives, cysts, or infection should be postponed until healing is complete. The most commonly observed side effects are swelling, redness, pain, bruising, tenderness, and itching at the injection site. These are typically mild in severity and typically resolve in less than 7 days. The incidence of swelling may be higher in patients under 36 years, and the incidence of bruising may be higher in patients over 35 years. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site. Do not implant into blood vessels. Use with caution in patients recently treated with anticoagulant or platelet inhibitors to avoid bleeding and bruising.

Treatment volume should be limited to 6.0 mL in wrinkles and folds, such as nasolabial folds, 1.5 mL per lip per treatment (*Restylane, Restylane-L,* and *Restylane Silk* only), and

1.0 mL for perioral rhytid correction (*Restylane Silk* only), as higher volume significantly increases moderate and severe injection site reactions. The safety or effectiveness of treatment in areas other than nasolabial folds, lips, and perioral rhytids has not been established in controlled clinical studies.

The *Restylane* family of products is available only through a licensed practitioner. Complete Instructions for Use are available at www.RestylaneUSA.com.

AECO-157A 05/15